VANCOUVER, Sept. 5 /CNW/ - Ondine Biopharma Corporation (TSX: OBP;
AIM: OBP), a medical technology company developing photodisinfection-based
products, today announced that a poster entitled "Photodisinfection in the
Treatment of Chronic Periodontitis" will be presented by Company
representatives at the American Academy of Periodontology's (AAP) annual
meeting. This year's AAP meeting is being held at the Washington State
Convention and Trade Center in Seattle, Washington on September 6-9, 2008.
"We are pleased to have the opportunity to present photodisinfection to
the U.S. periodontal community," said Carolyn Cross, Ondine's President and
CEO. "This peer-reviewed poster highlights the positive results of the
Company's Multi-Centre Trial using its Photodisinfection System. Periodontal
pockets treated with photodisinfection (220mW laser plus photosensitizer) in
addition to scaling and root planing (SRP) yielded statistically significant
reductions in pocket depth (p=0.01) as well as increases in clinical
attachment level (p=0.002) when compared to pockets treated only with SRP."
About Ondine Biopharma Corporation
Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on developing and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is based in Vancouver, British Columbia,
Canada, with a research and development laboratory in Bothell, Washington,
USA, and an international office in St. Michael, Barbados. For additional
information, please visit the Company's website at: www.ondinebiopharma.com.
Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's public filings.
The TSX Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
For further information:
For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
email@example.com; Adam Peeler, Investor Relations, The Equicom Group
Inc., (416) 815-0700 ext. 225, firstname.lastname@example.org; Canaccord Adams Ltd,
Nominated Adviser & Broker, Neil Johnson, Ryan Gaffney, +4420 7050 6500